VIA
SLN

Virtus Investment Advisers’s Silence Therapeutics SLN Stock Holding History

Virtus Investment Advisers’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,374
Closed -$106K – 535
2025
Q3 		$106K Buy
20,374
+3,537
+21% +$19.6K 0.03% 421
2025
Q2 		$97.7K Sell
16,837
-8,035
-32% -$34.4K 0.03% 342
2025
Q1 		$70.1K Buy
+24,872
New +$121K 0.02% 456

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Virtus Investment Advisers's SLN Position: Q4 2025 in Review

Virtus Investment Advisers sold out of Silence Therapeutics (SLN) in Q4 2025, closing a stake of 20,374 shares — an estimated $106K sold.

Virtus Investment Advisers first reported a position in SLN in Q1 2025 and held it in 3 quarters. The position peaked at $106K in Q3 2025. 58 funds tracked by Wall St. Rank hold SLN as of Q4 2025.

  • Virtus Investment Advisers reported no remaining Silence Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Virtus Investment Advisers sold 20,374 Silence Therapeutics shares in Q4 2025, an estimated $106K.
  • Virtus Investment Advisers first reported a position in Silence Therapeutics in Q1 2025 and held it in 3 quarters.
  • Virtus Investment Advisers's Silence Therapeutics position peaked at $106K in Q3 2025.
  • 58 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2025.

Based on Virtus Investment Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.